Abstract To study the clinical characteristics of hypereosionophilic syndrome and chronic eosinophilic leukemia (HES/CEL) in Japan, the clinical data of 29 HES/CEL patients throughout the country were surveyed. Moreover, the involvement of the FIP1L1-aPDGFR fusion gene resulting from a cryptic del (4)(q12q12) was examined in 24 cases. The FIP1L1-aPDGFR messenger RNA (mRNA) was detected in three patients (13% of patients fulfilled WHO criteria and 17% of Chusid criteria). One had a novel fusion transcript, which skipped the exon 12 of aPDGFR. The transcript appears to be generated by a splicing mechanism that is different from the previously reported splicing patterns. In silico analysis, the exon skipping was not related to a disruption of the exonic splicing enhancers within the exon but strongly associated with the loss of the vast majority of the FIP1L intron 8a where intronic splicing enhancers were accumulated. Unexpectedly, pseudo-chimera DNA fragments with some shared characteristic features were occasionally generated from healthy control samples by reverse transcriptase polymerase chain reaction (RT-PCR). Considering the relatively low incidence of the FIP1L1-a PDGFR transcript positive case, extreme care must therefore be taken when making a diagnosis using RT-PCR before imatinib therapy.
Introduction
Hypereosinophilic syndrome (HES) and chronic eosinophilic leukemia (CEL) are heterogeneous disorders characterized by prolonged eosinophilia. There are two commonly used diagnostic criteria proposed by Chusid et al. in 1975 [1] and by the World Health Organization (WHO) in 2001 [2] . The former includes (1) eosinophilia exceeding 1.5×10 9 /l and persisting for more than 6 months, (2) no secondary cause such as allergies or helminthic infection, and (3) evidence of eosinophil-mediated tissue damage. The latter consists of (1) persistent eosinophilia exceeding 1.5×10 9 /l, (2) increased numbers of bone marrow eosinophils and myeloblasts under 20% in blood or bone marrow, and (3) exclusion of known causes of eosinophilia, including clonal or abnormal T-cell populations. If clonal proliferation of eosinophils can be demonstrated, HES is reclassified as CEL [2] .
Most HES patients exhibit normal karyotypes by conventional cytogenetics. Recently, an 800 kb interstitial deletion on 4q12 resulting in the fusion of the FIP1-like-1 gene (FIP1L1) and the alpha-type platelet-derived growth factor receptor gene (aPDGFR) was identified to be a cause of HES/CEL [3, 4] . Platelet-derived growth factor (PDGF) was first identified as a major connective tissue cell mitogen that plays a role in atherosclerosis and wound healing. Thereafter, the finding that the PDGF B-chain gene is a human homologue of a viral oncogene, v-sis, expedited understanding the molecular mechanisms of human oncogenesis. The autophosphorylated alpha-and beta-type PDGFR (βPDGFR) stimulated by dimeric PDGF isoforms transduce the intracellular signaling for cell proliferation [5] . Moreover, the mitogenic signaling pathways in mesenchymal stromal cells can be reconstituted by the ectopic expression of these receptor genes in hematopoietic cells [6] . Since the 1990s, genomic mutations of a and bPDGFR had been found in various types of human leukemia, such as chronic myelogenous leukemia with t(4;22) or t(5;10) [7] [8], chronic myelomonocytic leukemia with t(5;12), t(5;7), or t(5;17) [9] [10] [11] , and acute myelogenous leukemia with t(5;14) [12] . Among them, FIP1L1-aPDGFR is a constitutively activated tyrosine kinase, which does not depend on dimerization but on the disruption of an autoinhibitory juxtamembrane domain encoded by exon 12 of aPDGFR [13] . A small molecule kinase inhibitor, imatinib is active not only for bcr/abl kinase but also for the PDGF receptorfamily kinases. Therefore, most HES patients with FIP1L1-aPDGFR show a dramatic response to imatinib [4, 14, 15] . Deletion of 4q12 with FIP1L1-aPDGFR is cytogenetically cryptic but can be detected by RT-PCR [3, 4] or fluorescence in situ hybridization (FISH) [16] .
The prevalence of FIP1L1-aPDGFR varies from 11 to 56% in each country reported. Cools et al. [4] first reported that the fusion gene was identified in 9 (56%) of 16 patients, whereas subsequent reports showed much lower prevalence: 11/81 (14%), 6/35 (17%), and 40/376 (11%) from the USA, France, and the UK, respectively [17] [18] [19] . So far, no nationwide survey data from Asia, including Japan, has yet been reported.
The first aim of this study was to examine the prevalence of FIP1L1-aPDGFR among Japanese HES/CEL by RT-PCR and examine the possible association between clinical characteristics and the expression of the fusion gene. During this study, a novel fusion transcript generated by skipping the exon 12 of aPDGFR was found. Thereafter, a novel mechanism of the aberrant splicing was also analyzed in silico.
Materials and methods

Patients
The clinical data of 29 Japanese patients with HES/CEL diagnosed by WHO or Chusid criteria between January 1995 and February 2007 were collected by questionnaires. Twenty-one patients were enrolled from the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG; http://www.jellsg.umin.jp), and eight patients were directly from a variety of nationwide hospitals. Peripheral blood (PB) samples were obtained from 24 cases among these patients. The gene analysis was approved by the Institutional Review Board of Kobe University Graduate School of Medicine (Protocol number 150023). Written informed consent was obtained from all patients.
RT-PCR
Ten milliliters of PB were collected in a tube containing ethylenediaminetetraacetic acid (EDTA) as an anti-coagulant from each patient. White blood cells (WBC) obtained by red cell lysis and/or mononuclear cells (MNC) isolated by density gradient centrifugation were stored at −80°C until RNA/DNA extraction.
Total RNA was isolated from WBC or MNC using the RNeasy kit (Qiagen) according to the manufacturer's recommendation including a step of DNase-1 treatment. Complementary DNA (cDNA) was synthesized from 0.4-1.7 μg of total RNA using the Superscript first-strand synthesis system (Invitrogen) with oligo (dT) primers. The FIP1L1-aPDGFR fusion transcript was confirmed by nested PCR using two primer sets. The primer set 1 was the same as described by Cools et al. [4] ; FIP1L1-F1, 5′ acctggtgctgatctttctgat 3′ and aPDGFR-R1, 5′ tgagag cttgtttttcactgga 3′ for the first step PCR, and FIP1L1-F2, 5′ aaagaggatacgaatgggacttg 3′ and aPDGFR-R2, 5′ gggaccggcttaatccatag 3′ for the second-step PCR. The forward primers of primer set 2 were modified as described by Score et al. [20] : FIP1L1-F3, 5′ cacctggaagcattaatggag 3′ and FIP1L1-F4, 5′ agttccactcttagaggtag 3′ for the first and second PCR, respectively.
A master PCR mixture was freshly prepared with final concentrations of 0.2 mM deoxyribonucleotide triphosphate (dNTP), 1.5 mM MgCl 2 , 5 μl of 10×PCR buffer containing 10 mM Tris-HCl (pH 8.0), 100 mM NaCl, 0.1 mM EDTA, 1 mM dithiothreitol (DTT), 50% glycerol and 1% TritonX-100, 1 μl of DMSO, 2.5 U of Taq polymerase and mixed with 30 pmol of each primer in a total volume of 50 μl. PCR was performed with an initial denaturation step of 3 min at 94°C followed by 35 cycles for first step at 94°C for 30 s, at 60°C for 20 s, and at 72°C for 1 min, and final elongation step of at 72°C for 7 min. Five microliters of each PCR product was used for next nested step for 20 cycles in a total volume of 50 μl.
Genomic PCR
Cell pellets of MNC or WBC are digested with 0.5 ml of lysis buffer [10 mM Tris-HCl (pH 8.5), 5 mM EDTA (pH 8.0), 200 mM NaCl, 0.2% (w/v) SDS] containing proteinase K to a final concentration of 0.12 mg/ml overnight in 55°C, followed by treatment with RNase A for 1 h at room temperature at a final concentration of 50 μg/ml. Genomic DNA was precipitated with an equal volume of isopropanol, extracted with a 100-μl pipette tip or pelleted, and then dissolved in 0.2 ml of distilled water. Amplification of 5 μl of digested DNA was performed using the Expand Long Template PCR System (Roche) in a total volume of 50 μl. The PCR cycling profile was as follows: denaturation at 94°C for 2 min followed by 25 cycles at 94°C for 10 s, 60°C for 30 s, 68°C for 2 min, and a final extension at 68°C for 7 min. Nested PCR was performed with 5 μl of first PCR products under the same conditions as the first.
Oligonucleotide primers used for the genomic PCR for Patient 005 were FIP1L1-F5, 5′-aagcatctaattaggtgaaactg 3′ and aPDGFR-R3 5′ aagttgtgtgcaagggaaaaggg 3′ for the first step, FIP1L1-F6, 5′ cagactataactatcagccg 3′ and aPDGFR-R4, 5′ gtccatctcttggaaactcc 3′ for the second step. Primers for Patients 017 and 038 were FIP1L1-F7, 5′ cagcacttcttctcagtctca 3′ and aPDGFR-R5, 5′ tgagagcttgtttttcactgga 3′ for the first step and FIP1L1-F8, 5′-gacaagtactgcctccagaa 3′ and aPDGFR-R6, 5′ gggaccggcttaatccatag 3′ for the nested step. Primers for 058 were FIP1L1-F9, 5′ catgggctttatcagtctcttta3′ and aPDGFR-R5 for the first step and FIP1L1-F10, gtgcttgtggaagtaaaacgta and aPDGFR-R6 for the second step.
Nucleotide sequencing
After agarose gel electrophoresis, amplified DNA fragments were purified (QIAEX II Gel Purification kit, Qiagen) and sequenced either directly, using an ABI Prism 310 Genetic Analyzer (Applied Biosystems) and a Big Dye Terminator DNA sequencing kit (Applied Biosystems). Homology searches were performed using the basic local alignment search tool (BLAST) program (http://www.ncbi.nlm.nih. gov/BLAST).
Results
Patient characteristics
The patient characteristics are summarized in Table 1 . Twenty-seven of the total 29 diagnostic HES/CEL patients fulfilled the WHO criteria, and 16 patients fulfilled the Chusid criteria, including 14 that overlapped. Two of the 16 patients diagnosed by Chusid criteria did not meet the WHO criteria because of insufficient examination of their bone marrow. Thirteen of 27 patients diagnosed by WHO criteria did not satisfy Chusid criteria; they did not demonstrate any specific symptoms or the eosinophilia persisted less than 6 months. In the patients who met the WHO criteria, the male/female ratio was 1.7:1 with a median age at diagnosis of 50 years (range, 17-87. The median eosinophil count was 11,900/μl (range, 2,200 to 60,700. Two patients with abnormal karyotype were classified as CEL; one had t(2;5)(p23;q31), and the other had der(1)t(1;12)(q32;q13), inv(7)(q22;q31). Twenty-three patients were symptomatic with fever of unknown origin, cough, hepatomegaly, skin lesions, and/or splenomegaly. Twenty-three were treated with corticosteroids (19 cases) or imatinib (4 cases). Three patients treated with imatinib achieved a complete response. Another patient discontinued imatinib within 2 days because of severe diarrhea and vomiting.
FIP1L1-aPDGFR mRNA positive HES/CEL
The expression of the FIP1L1-aPDGFR fusion transcript was assayed by RT-PCR using primer sets 1 and 2 in 24 cases. FIP1L1-aPDGFR mRNA was reproducibly detectable in three patients (005, 017, and 058) by both primer sets (Fig. 1) . Patients 005 and 017 were males, age 43, with normal karyotypes by the conventional G-banding method. The clinical characteristics of 005 were described previously [21] . Briefly, he had a fever of unknown origin, cardiac murmur, hepatosplenomegaly, leukocytosis (WBC 17.2×10 9 /l, 60% eosinophils, 5% blasts), anemia (hemoglobin 6.9 g/dl), and thrombocytopenia (51.9×10 9 /l). The bone marrow aspirate showed a nucleated cell count of 130×10 9 /l, 3.6% blasts, and 65% eosinophils. Patient 017 did not have significant symptoms except for a persistent cough. A blood examination showed peripheral blood leukocytosis (WBC count of 35.8×10 9 /l with 35% eosinophils and 0% blasts) and mild anemia (hemoglobin 12.8 g/dl) accompanied by bone marrow eosinophilia (37%). These two patients were administered imatinib therapy and achieved a complete response. Patient 058 was male at age 26 with a fever of unknown origin, cough, cardiac murmur, congestive heart failure with mitral-valve disorder, and splenomegaly. A blood examination showed leukocytosis (WBC count of 21.5×10 9 /l with 59% eosinophils and 0% blasts) and anemia (hemoglobin 9.2 g/dl) accompanied by bone marrow eosinophilia (36%) with normal karyotype by the G-banding method. While the administration of prednisolone had no significant effect on eosinophilia, a low dose of imatinib (100 mg/day) was found to induce a complete remission. This case met the WHO criteria but not the Chusid criteria because the diagnosis was done at only 2 months from the onset. It was difficult to distinguish FIP1L1-aPDGFR positive cases from negative ones by physical appearance and/or by other laboratory findings (Table 1) . Meanwhile, a FIP1L1-aPDGFR chimera cDNA fragment of Patient 038 was amplified by primer set 2 but not by primer set 1 (Fig. 1a) . It appeared to be pseudopositive because a chimera gene was not amplified from the patient's genomic DNA as described below (Fig. 1b) .
Nucleotide sequences of the chimera transcripts
In case 005, FIP1L1 exon 9 was fused to a truncated exon 12 of aPDGFR with a breakpoint at nucleotide numbers 1160 of FIP1L1 mRNA (GenBank accession number NM030917) and 1877 of aPDGFR (M21574; Fig. 2 , 005 type 1). There was another splice variant, which lacked the FIP1L1 exon 8a but had the same breakpoint (005 type 2). In 017, the FIP1L1 exon 8a was fused to the aPDGFR exon 13 with a breakpoint at nucleotide 1066 and 1926, respectively. In 058, the truncated intron 8a of FIP1L1 at nucleotide 1627077 of the human chromosome 4 genome (GenBank accession number NT22853) was fused to truncated exon 12 of aPDGFR at nucleotide 1864. Case 058 also had splice variant without the FIP1L1 exon 7 (058 type 2). All of the transcripts were in frame. The cDNA fragment amplified by primer set 1 in 038 had FIP1L1-aPDGFR chimera sequences similar to those of 005, 017, and 058 (Fig. 2) . In 038, however, two additional nucleotides 'TA' of unknown origin were found at the breakpoint of the FIP1L1 exon 8a (nucleotide 1066) and of the truncated exon12 of aPDGFR (nucleotide 1863). The characteristic nucleotide insertion suggested that the DNA fragment amplified from 038 was not a contamination from other FIP1L1-aPDGFR positive samples.
Genomic analysis of the FIP1L1-aPDGFR chimera gene
The FIP1L1-aPDGFR fusion gene was amplified by genomic PCR in three patients (005, 017, and 058) but not in 038 or healthy controls (Fig. 1b) . The genomic breakpoints of the fusion genes were shown in Fig. 3 . In 005, the FIP1L1 intron 9 at nucleotide 1632015 (NT22853) fused to the truncated aPDGFR exon 12 at nucleotide 2480965. In 017, the FIP1L1 intron 8a at 1622282 fused to the aPDGFR exon 12 at 2480961. In 058, the FIP1L1 intron 8a at 1627077 fused to the aPDGFR exon 12 at 2480962. The splicing pattern was different in each patient. Two types of splicing pattern of the fusion gene have been reported [22] . The splice patterns of 005 and 058 were types II and I, respectively. The cryptic splice sites located at 10 and 31 bp from the breakpoint in 005 and 058, respectively. Those were close to the breakpoint, as those reported previously [4, 15, 18, 19, 22] . In contrast, the fusion transcript of 017 was generated by DNA splicing using a 5′donor splice site of the FIP1L1 intron 8a and a 3′ authentic acceptor site of the aPDGFR exon 13. This is the first case with the FIP1L1-aPDGFR transcript skipping the aPDGFR exon 12, which is not consistent with any types of splicing pattern reported [22] .
The lack of amplification of the chimera gene by genomic PCR in case 038 also supports the speculation that the FIP1L1-aPDGFR fusion DNA fragment detected by RT-PCR was generated artificially. Therefore, we examined Fig. 2 The structure of FIP1L1-α aPDGFR fusion transcripts. The structure of FIP1L1-α aPDGFR mRNAs of 005, 017, and 058 are illustrated. There are alternative splice variants (type 2) without exon 8a and exon 7 in 005 and 058, respectively. The exons of FIP1L1 and α aPDGFR are shown in green and red boxes, respectively. Gray boxes indicate a truncated intron 8a of FIP1L1. Arrows indicate the position of PCR primers used. The nucleotide numbers of each mRNA (The GenBank accession number is NM030917 for FIP1L1, M21574 for α aPDGFR) are shown below the boxes The nucleotide sequences around the breakpoint are also shown in each transcript. The fusion-point of 038 was similar to that of 058, but an additional nucleotides 'TA' insertion (a white box) was found whether a pseudo-FIP1L1-aPDGFR chimera DNA fragment could be amplified in healthy individuals by RT-PCR. Surprisingly, chimera cDNA fragments were detected in two of seven healthy normal controls by using one of two primer sets occasionally (one of several PCR reactions in each sample) but not by both sets. The chimera cDNA fragments derived from the healthy controls showed the same characteristics of case 038 with 'TA' insertion adjacent to the breakpoint at nucleotide 1863 of the truncated aPDGFR exon 12 (Fig. 4) . Genomic PCR failed to show any rearrangements in healthy controls as well as in case 038.
In silico analysis of the splicing mechanism skipping the aPDGFR exon 12
Because the cryptic splice sites were located close to the breakpoints of cases 005 and 058 as well as those of all cases reported previously [4, 15, 18, 19, 22] , the sequences around the splice sites, approximately 100 bp from the breakpoint were analyzed using a web-based resource ASD [23] . There were several candidate sequences to substitute the classical splicing signals such as 3′ splice site, branch site, and polypyrimidine tract at the intron-exon boundary in 017 and in other cases (data not shown). Therefore, the nucleotide sequences upstream of the breakpoint of aPDGFR exon12 could not seem to explain the differences of the splicing pattern.
Next, the auxiliary motifs named exonic splicing enhancers (ESEs) that are used by the splicing machinery for recognizing exon-intron junctions were assessed using web-based resources, ESE-finder [24] and RESCUE-ESE [25] . The genomic breakpoints of aPDGFR exon12 in three patients were closely located within a 4-bp distance. New ESE motifs were created at the breakpoint of aPDGFR exon 12 in all cases (data not shown). This means that no relationship was observed between the breakpoint and the splicing type.
Thereafter, the differences in intronic auxiliary motifs named intronic splicing enhancers (ISE) were further analyzed. The number of ISE motifs every 500 nucleotides were examined using web-based resource, RESCUE-ISE [26] . In FIP1L1 intron 8a, there are three ISE motif peaks of over 0.1 in the frequency (the number of motif per nucleotide; Fig. 5 ). The first peak contained known ISE motifs, the repetitive dinucleotides (CA) 12 (CU) 28 from nucleotides 1623790 to 1623869 of the human chromosome 4 genome (NT22853). The second and third peaks were composed of overlapped multiple divergent motifs, but they did not match any ISE motifs identified by mutational analysis [27] . The breakpoints of case 058 and [22] other cases reported by Klion et al. [28] and Cools et al. [4] in the FIP1L1 intron 8a were located between the second and third peaks, whereas case 017 lost all three peaks as shown in Fig. 5 . Taken together, the exon skipping of 017 was probably due to the loss of a vast majority of FIP1L1 intron 8a and the ISE motifs.
Discussion
The incidence of the FIP1L1-aPDGFR fusion gene in Japanese HES (13% in WHO, 17% in Chusid) was similar to those described in recent reports from Western countries (10-20%) [17] [18] [19] . All FIP1L1-aPDGFR-positive cases in this study are male. The male predominance is compatible with previous reports [4, 22] . There was no trend of difference in other clinical features listed in Table 1 between FIP1L1-aPDGFR-positive and negative patients, although the number of positive cases is too low to compare statistically. Therefore, it is critical to examine the FIP1L1-aPDGFR fusion gene of HES because imatinib therapy is expected to provide a complete response for the fusion gene positive cases [4, 14, 15, 19] .
This study found an aberrant fusion transcript skipping the aPDGFR exon 12. A comparative analysis of splicing mechanisms of exon inclusion and skipping revealed that [28] are also indicated by arrows Fig. 4 The structure of the FIP1L1-α aPDGFR chimera DNA fragments amplified in normal individuals. The structures of pseudo-chimera DNA fragments detected in healthy individuals are shown. The FIP1L1-α aPDGFR chimera was detected in two of seven healthy individuals: Normal 1 and Normal 2. The chimera DNA was detected only by primer set 2 in Normal 1 but only by primer set 1 in Normal 2.
Both showed the breakpoints at FIP1L1 exon 8a and α aPDGFR exon 12, with all transcripts accompanied by an additional two nucleotide insertion (white boxes). Arrows indicate the position of PCR primers used. The nucleotide sequences around the breakpoint are shown. The corresponding nucleotide numbers of each mRNA are also shown as indicated in Fig. 2 the difference may depend on the site of the breakpoint in the FIP1L1 intron. The exon skipping is possibly due to the loss of the dinucleotide repeats as known ISE sequences and/or the loss of accumulated multiple hexameric ISE motifs. Simple repeats such as the (CA) 12 (CU) 28 deleted in 017 could affect splicing efficiency or splice site choice [29] . For example, the CA-repeat, which was found in intron 13 of the human endothelial NO synthetase gene, could function either as splicing enhancers or silencers, depending on their proximity to the alternative 5′ splice site [30] . The CUCUCU element is required for splicing repression and binds to the polypyrimidine tract binding protein or its neuronal homolog (PTB/nPTB). It is often found in the polypyrimidine tract of regulated 3′ splice sites [31] . Those are considered to be strong signals that are important for efficient splicing. Meanwhile, the distribution of the ISE motif such as the second and third peaks in FIP1L1 intron 8a is composed of the accumulation of multiple hexameric motifs. These sites with a high distribution of ISE motifs may also be responsible to recognize the downstream sequence of the aPDGFR exon 12. This explanation is also consistent with the current exon recognition model; initial splice-site recognition is achieved by the accumulation of multiple weak signals, not by a few strong signals [27, [32] [33] [34] . It is interesting to elucidate whether the latent exon 12 skipping of aPDGFR is rare or not to understand the splicing mechanism of the FIP1L1-aPDGFR fusion gene.
These experiments also found an amplification of pseudo-FIP1L1-aPDGFR DNA fragments from healthy controls by RT-PCR. Sequence analysis revealed that the recombination of the pseudo-chimera occurred between FIP1L1 exon 8a and aPDGFR exon 12 and that two nucleotides 'TA' were commonly inserted at the breakpoint. Therefore, this in vitro recombination is not random, but it instead seemed to mimic the genetic recombination in vivo.
Using a RT-PCR analysis, several aberrant mutations in normal controls have been reported in differential processing: in blood storage [35] , during RT-PCR [36] , and the PCR reaction [37] . These artificial mutations also occurred in mutational hotspots and mimic a fusion formation. The artificial recombination between FIP1L1 and aPDGFR transcripts is thought to be produced in the process of PCR amplification because the artifact chimera formation was occasionally generated using a same cDNA sample. Several mechanisms of an artificial chimera formation during PCR have thus been proposed [38] , although it is difficult to explain the molecular mechanism of the pseudo FIP1L1-aPDGFR chimera formation. The FIP1L1-aPDGFR fusion gene/transcript was usually examined by nested PCR because of the low expression of the fusion gene [4, 20] , which may contribute to a sufficient amplification of the pseudo-chimera. The breakpoints of the atypical chronic myeloid leukemia with the BCR-aPDGFR fusion gene associated with t(4;22)(q12;q11) also fell in the aPDGFR exon12 [7, 39] . Therefore, the site at the aPDGFR exon 12 may be highly susceptible to become rearranged during in vivo DNA replication and even in vitro during PCR. The molecular mechanism of in vitro recombination may offer the key to understand the DNA recombination in HES/CEL.
Meanwhile, these mutational hotspots in vitro could easily lead to a misdiagnosis. It is therefore necessary to be careful when making a diagnosis of HES with FIP1L1-aPDGFR by RT-PCR. To rule out pseudo-positive cases, repeated RT-PCR with several primer sets, genomic PCR, and/or a FISH analysis may be useful to confirm the presence of the FIP1L1-aPDGFR fusion gene.
